Thursday, 15 October 2026European Markets

GPE GROUP PIZZORNO Stock Jumps By 31% In The Last 21 Sessions

Loading stream...

(vianews) - shares of gpe group pizzorno (cac 40: gpe.pa) rose by a staggering 31.65% in 21 sessions from €43.6 to €57.40 at 17:55 est on wednesday, after two successive sessions in a row of losses. cac 40 is dropping 0% to €7,208.87, following the last session's upward trend.

about gpe group pizzorno

groupe pizzorno environnement provides environmental services primarily in france. it engages in the production and recycling of secondary raw materials; development of technologies and services for the recovery of bio-waste; production of heat and electricity from waste treatment; and processing and collection of household waste, as well as offers cleanliness services. groupe pizzorno environnement was founded in 1974 and is headquartered in draguignan, france.

earnings per share

as for profitability, gpe group pizzorno has a trailing twelve months eps of €5.16.

pe ratio

gpe group pizzorno has a trailing twelve months price to earnings ratio of 11.12. meaning, the purchaser of the share is investing €11.12 for every euro of annual earnings.

more news about gpe group pizzorno (gpe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com